Hori R, Okamura N, Aiba T, Tanigawara Y
Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Japan.
J Pharmacol Exp Ther. 1993 Sep;266(3):1620-5.
The mechanism for renal tubular secretion of digoxin as well as its interaction with quinidine or verapamil were investigated using the isolated perfused rat kidney. [3H]Digoxin was instantaneously administered into the renal artery together with [14C]inulin and Evans blue-albumin, and renal venous and urinary outflow curves were measured. The ratio of fractional excretion to filtration fraction for digoxin was 2.40 +/- 0.40, indicating involvement of tubular secretion. Quinidine and verapamil decreased the ratio of fractional excretion to filtration fraction in a concentration-dependent manner, and this inhibition was indicated to occur at transport from cells to lumen across luminal membranes. Neither tetraethylammonium nor p-aminohippurate affected the renal handling of digoxin. Because ouabain and digitoxose showed no influence on the value of fractional excretion to filtration fractions, Na+,K(+)-ATPase is not involved in the tubular secretion of digoxin. A metabolic inhibitor, 2,4-dinitrophenol, markedly inhibited digoxin secretion. Agents that bind to P-glycoprotein, such as vinblastine, daunorubicin and reserpine, markedly inhibited the secretion of digoxin. Recently, we have found that digoxin is a substrate transported by P-glycoprotein. The findings obtained here support the hypothesis that digoxin is secreted by P-glycoprotein located on the luminal membrane of renal tubular epithelial cells, and that clinically important interactions with quinidine and verapamil are caused by the inhibition of P-glycoprotein.
利用离体灌注大鼠肾脏研究了地高辛的肾小管分泌机制及其与奎尼丁或维拉帕米的相互作用。将[3H]地高辛与[14C]菊粉和伊文思蓝白蛋白一起瞬间注入肾动脉,并测量肾静脉和尿流出曲线。地高辛的排泄分数与滤过分数之比为2.40±0.40,表明存在肾小管分泌。奎尼丁和维拉帕米以浓度依赖的方式降低排泄分数与滤过分数之比,且这种抑制作用表明发生在从细胞到管腔穿过管腔膜的转运过程中。四乙铵和对氨基马尿酸均不影响地高辛的肾脏处理。由于哇巴因和洋地黄毒糖对排泄分数与滤过分数的值无影响,因此Na +,K(+)-ATP酶不参与地高辛的肾小管分泌。代谢抑制剂2,4-二硝基苯酚显著抑制地高辛分泌。与P-糖蛋白结合的药物,如长春碱、柔红霉素和利血平,显著抑制地高辛分泌。最近,我们发现地高辛是一种由P-糖蛋白转运的底物。此处获得的研究结果支持以下假设:地高辛由位于肾小管上皮细胞管腔膜上的P-糖蛋白分泌,与奎尼丁和维拉帕米的临床重要相互作用是由P-糖蛋白的抑制引起的。